Koronis Pharmaceuticals, Inc. Clinical Trial Results Demonstrate Promise for First Non-suppressive HIV Drug
1/20/2011 10:40:11 AM
(BUSINESS WIRE)--Recently published Phase 2a clinical trial results (accessible by clicking here) show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism. Koronis is planning a follow-on Phase 2 trial to determine the treatment duration required to achieve a clinically meaningful decrease in a patient’s viral load.
comments powered by